Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday that the first patient has been enrolled in a clinical trial evaluating bemcentinib, its AXL kinase inhibitor, in combination with pacritinib, a JAK2 inhibitor.
The trial, sponsored by the Mays Cancer Center at UT Health San Antonio, will investigate this combination therapy in patients with lung adenocarcinoma.
Pacritinib is marketed in the United States as VONJO and is owned by biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI).
The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas